Peter A. Prieto

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, and we performed studies to test the(More)
  • 1